Area of research
Virology · Immunology
Research interest
Research interests include HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, Immune Cell Function and Interaction, and vaccines and immunoinformatics approaches.
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming.
Persistent serum protein signatures define an inflammatory subcategory of long COVID.
A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses.
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults
Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.
Vaccine Induction of Heterologous HIV-1 Neutralizing Antibody B Cell Lineages in Humans
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1–uninfected adult participants in the US
Vaccination induces HIV broadly neutralizing antibody precursors in humans
Vaccination induces HIV broadly neutralizing antibody precursors in humans.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate
Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
Th2-Biased Transcriptional Profile Predicts HIV Envelope-Specific Polyfunctional CD4<sup>+</sup> T Cells That Correlated with Reduced Risk of Infection in RV144 Trial.
Persistent serum protein signatures define an inflammatory subset of long COVID
Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim Analysis
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence